167 related articles for article (PubMed ID: 33633213)
1. A novel technology to integrate imaging and clinical markers for non-invasive diagnosis of lung cancer.
Shaffie A; Soliman A; Fu XA; Nantz M; Giridharan G; van Berkel V; Khalifeh HA; Ghazal M; Elmaghraby A; El-Baz A
Sci Rep; 2021 Feb; 11(1):4597. PubMed ID: 33633213
[TBL] [Abstract][Full Text] [Related]
2. A volatile biomarker in breath predicts lung cancer and pulmonary nodules.
Phillips M; Bauer TL; Pass HI
J Breath Res; 2019 Jun; 13(3):036013. PubMed ID: 31085817
[TBL] [Abstract][Full Text] [Related]
3. Breath carbonyl compounds as biomarkers of lung cancer.
Li M; Yang D; Brock G; Knipp RJ; Bousamra M; Nantz MH; Fu XA
Lung Cancer; 2015 Oct; 90(1):92-7. PubMed ID: 26233567
[TBL] [Abstract][Full Text] [Related]
4. A Generalized Deep Learning-Based Diagnostic System for Early Diagnosis of Various Types of Pulmonary Nodules.
Shaffie A; Soliman A; Fraiwan L; Ghazal M; Taher F; Dunlap N; Wang B; van Berkel V; Keynton R; Elmaghraby A; El-Baz A
Technol Cancer Res Treat; 2018 Jan; 17():1533033818798800. PubMed ID: 30244648
[TBL] [Abstract][Full Text] [Related]
5. Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening.
Phillips M; Bauer TL; Cataneo RN; Lebauer C; Mundada M; Pass HI; Ramakrishna N; Rom WN; Vallières E
PLoS One; 2015; 10(12):e0142484. PubMed ID: 26698306
[TBL] [Abstract][Full Text] [Related]
6. Volatile signature for the early diagnosis of lung cancer.
Gasparri R; Santonico M; Valentini C; Sedda G; Borri A; Petrella F; Maisonneuve P; Pennazza G; D'Amico A; Di Natale C; Paolesse R; Spaggiari L
J Breath Res; 2016 Feb; 10(1):016007. PubMed ID: 26857451
[TBL] [Abstract][Full Text] [Related]
7. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
8. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer.
Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P
J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249
[TBL] [Abstract][Full Text] [Related]
9. VOC biomarkers identification and predictive model construction for lung cancer based on exhaled breath analysis: research protocol for an exploratory study.
Li W; Dai W; Liu M; Long Y; Wang C; Xie S; Liu Y; Zhang Y; Shi Q; Peng X; Liu Y; Li Q; Duan Y
BMJ Open; 2019 Aug; 9(8):e028448. PubMed ID: 31399453
[TBL] [Abstract][Full Text] [Related]
10. Comparison of volatile organic compounds from lung cancer patients and healthy controls-challenges and limitations of an observational study.
Schallschmidt K; Becker R; Jung C; Bremser W; Walles T; Neudecker J; Leschber G; Frese S; Nehls I
J Breath Res; 2016 Oct; 10(4):046007. PubMed ID: 27732569
[TBL] [Abstract][Full Text] [Related]
11. Quantitative breath analysis of volatile organic compounds of lung cancer patients.
Song G; Qin T; Liu H; Xu GB; Pan YY; Xiong FX; Gu KS; Sun GP; Chen ZD
Lung Cancer; 2010 Feb; 67(2):227-31. PubMed ID: 19409642
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease.
Bousamra M; Schumer E; Li M; Knipp RJ; Nantz MH; van Berkel V; Fu XA
J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1074-80; discussion 1080-1. PubMed ID: 25129599
[TBL] [Abstract][Full Text] [Related]
13. Assessment of an Exhaled Breath Test Using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry to Detect Lung Cancer.
Meng S; Li Q; Zhou Z; Li H; Liu X; Pan S; Li M; Wang L; Guo Y; Qiu M; Wang J
JAMA Netw Open; 2021 Mar; 4(3):e213486. PubMed ID: 33783517
[TBL] [Abstract][Full Text] [Related]
14. An Assisted Diagnosis System for Detection of Early Pulmonary Nodule in Computed Tomography Images.
Liu JK; Jiang HY; Gao MD; He CG; Wang Y; Wang P; Ma H; Li Y
J Med Syst; 2017 Feb; 41(2):30. PubMed ID: 28032305
[TBL] [Abstract][Full Text] [Related]
15. Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer.
van Keulen KE; Jansen ME; Schrauwen RWM; Kolkman JJ; Siersema PD
Aliment Pharmacol Ther; 2020 Feb; 51(3):334-346. PubMed ID: 31858615
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive breath analysis of pulmonary nodules.
Peled N; Hakim M; Bunn PA; Miller YE; Kennedy TC; Mattei J; Mitchell JD; Hirsch FR; Haick H
J Thorac Oncol; 2012 Oct; 7(10):1528-33. PubMed ID: 22929969
[TBL] [Abstract][Full Text] [Related]
17. Association of Smoking with Metabolic Volatile Organic Compounds in Exhaled Breath.
Chen X; Wang F; Lin L; Dong H; Huang F; Ghulam Muhammad K; Chen L; Gorlova OY
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29068415
[TBL] [Abstract][Full Text] [Related]
18. High sensitivity for lung cancer detection using analysis of exhaled carbonyl compounds.
Schumer EM; Trivedi JR; van Berkel V; Black MC; Li M; Fu XA; Bousamra M
J Thorac Cardiovasc Surg; 2015 Dec; 150(6):1517-22; discussion 1522-4. PubMed ID: 26412316
[TBL] [Abstract][Full Text] [Related]
19. Infrared cavity ring-down spectroscopy for detecting non-small cell lung cancer in exhaled breath.
Larracy R; Phinyomark A; Scheme E
J Breath Res; 2022 Mar; 16(2):. PubMed ID: 35294929
[TBL] [Abstract][Full Text] [Related]
20. Localized thin-section CT with radiomics feature extraction and machine learning to classify early-detected pulmonary nodules from lung cancer screening.
Tu SJ; Wang CW; Pan KT; Wu YC; Wu CT
Phys Med Biol; 2018 Mar; 63(6):065005. PubMed ID: 29446758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
